Company · Public · NTLA
Intellia Therapeutics
Clinical-stage genome editing company with in vivo CRISPR programmes in amyloidosis and hereditary angioedema.
EvidenceStrongDurability extended
Listing
Public
Ticker
NTLA
Headquarters
Cambridge, US
Founded
2014
Technology
In vivo CRISPR gene editing
Category
Market cap
$2.4B
Longevity thesis
Durable in vivo editing turns chronic disease management into single-administration treatment — the delivery template later longevity interventions will need.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| NTLA-2002 | Phase 3 | Hereditary angioedema |
| nex-z | Phase 3 | ATTR amyloidosis |
Recent developments
- 5 Aug 2026Reported extended durability of knockdown at 24 months.
Scientific evidence
EvidenceStrong
Human Phase 3 data with multi-year durability follow-up.
LONGEFI analysis
Relevant to longevity mainly as delivery-platform validation. Each durability update makes in vivo editing of aging-related targets more plausible.
Analysis is research commentary. It is not investment advice or a recommendation.